FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989938285> ?p ?o ?g. }

• W2989938285 abstract "Frequent mutation of genes in the PI3K/AKT/mTOR signaling pathway in human cancers has stimulated large investments in over 40 small molecule therapeutic drugs but most have low efficacy in patients. As a result, cancers with high PI3K pathway activity such as triple-negative breast cancer (TNBC) are still treated primarily with conventional chemotherapy. By systematically analyzing responses of TNBC cells to a diverse collection of PI3K pathway inhibitors with varying degrees of polyselectivity, we find that the preclinical compound Torin2 and related analogs are unusually effective because they inhibit both mTORC1/2 and structurally related PI3K-like kinases (PIKKs). The activity of Torin2 in TNBC cells is most closely mimicked by combining selective inhibitors of mTORC1/2 and Chk1, a kinase that acts downstream of the PIKKs ATR and DNA-PK in the signaling response to replication stress. Torin2 is more cytotoxic in TNBC/basal-like cell lines (N=19) than clinical grade mTORC1/2 inhibitors such as sapanisertib, but produces no cytotoxicity in non-transformed cells with basal-like gene expression (N=2). The high activity of Torin2 in TNBC is associated with greater activation of caspase-dependent apoptosis and stronger inhibition of cell proliferation than conventional PI3K/AKT/mTOR inhibitors, which do not inhibit PIKKs. Pulse-labeling studies with thymidine analogs and live-cell imaging of cells expressing fluorescent cell cycle reporters show that unlike other PI3K pathway drugs, Torin2 blocks progression of S phase, thereby causing accumulation of single-stranded DNA, DNA damage and death by replication catastrophe or mitotic failure. These phenotypes appear to result from co-targeting distinct pathways required during S phase in TNBC cells: inhibiting mTOR perturbs de novo biosynthesis and salvage of pyrimidines and purines, and inhibiting PIKKs causes high levels of replication stress and DNA damage. Moreover, computational models developed to better understand the complex cell cycle mechanism of action of Torin2 demonstrate the importance of co-targeting S-phase vulnerabilities for cytotoxicity. Thus, Torin2 and related analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC and possibly to other cancer cells. This insight could be translated therapeutically by further developing Torin2 analogs or combinations of existing mTOR and PIKK inhibitors. Citation Format: Sameer S. Chopra, Annie Jenney, Adam Palmer, Mario Niepel, Mirra Chung, Caitlin Mills, Sindhu Carmen Sivakumaren, Qingsong Liu, Jia-Yun Chen, Clarence Yapp, Nathanael S. Gray, Peter K. Sorger. Torin2 and related analogs exploit replicative and checkpoint vulnerabilities to induce death of triple-negative breast cancer cells [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B103. doi:10.1158/1535-7163.TARG-19-B103" @default.
• W2989938285 created "2019-12-05" @default.
• W2989938285 creator A5008745121 @default.
• W2989938285 creator A5015241228 @default.
• W2989938285 creator A5016961938 @default.
• W2989938285 creator A5022352605 @default.
• W2989938285 creator A5022984032 @default.
• W2989938285 creator A5040454293 @default.
• W2989938285 creator A5045454230 @default.
• W2989938285 creator A5049217703 @default.
• W2989938285 creator A5049302160 @default.
• W2989938285 creator A5051189984 @default.
• W2989938285 creator A5056391726 @default.
• W2989938285 creator A5067229525 @default.
• W2989938285 date "2019-12-01" @default.
• W2989938285 modified "2023-10-14" @default.
• W2989938285 title "Abstract B103: Torin2 and related analogs exploit replicative and checkpoint vulnerabilities to induce death of triple-negative breast cancer cells" @default.
• W2989938285 doi "https://doi.org/10.1158/1535-7163.targ-19-b103" @default.
• W2989938285 hasPublicationYear "2019" @default.
• W2989938285 type Work @default.
• W2989938285 sameAs 2989938285 @default.
• W2989938285 citedByCount "0" @default.
• W2989938285 crossrefType "proceedings-article" @default.
• W2989938285 hasAuthorship W2989938285A5008745121 @default.
• W2989938285 hasAuthorship W2989938285A5015241228 @default.
• W2989938285 hasAuthorship W2989938285A5016961938 @default.
• W2989938285 hasAuthorship W2989938285A5022352605 @default.
• W2989938285 hasAuthorship W2989938285A5022984032 @default.
• W2989938285 hasAuthorship W2989938285A5040454293 @default.
• W2989938285 hasAuthorship W2989938285A5045454230 @default.
• W2989938285 hasAuthorship W2989938285A5049217703 @default.
• W2989938285 hasAuthorship W2989938285A5049302160 @default.
• W2989938285 hasAuthorship W2989938285A5051189984 @default.
• W2989938285 hasAuthorship W2989938285A5056391726 @default.
• W2989938285 hasAuthorship W2989938285A5067229525 @default.
• W2989938285 hasConcept C121608353 @default.
• W2989938285 hasConcept C184235292 @default.
• W2989938285 hasConcept C186000732 @default.
• W2989938285 hasConcept C190283241 @default.
• W2989938285 hasConcept C2780110267 @default.
• W2989938285 hasConcept C29537977 @default.
• W2989938285 hasConcept C31573885 @default.
• W2989938285 hasConcept C502942594 @default.
• W2989938285 hasConcept C530470458 @default.
• W2989938285 hasConcept C54355233 @default.
• W2989938285 hasConcept C55493867 @default.
• W2989938285 hasConcept C62478195 @default.
• W2989938285 hasConcept C75217442 @default.
• W2989938285 hasConcept C86554907 @default.
• W2989938285 hasConcept C86803240 @default.
• W2989938285 hasConcept C95444343 @default.
• W2989938285 hasConcept C98490376 @default.
• W2989938285 hasConceptScore W2989938285C121608353 @default.
• W2989938285 hasConceptScore W2989938285C184235292 @default.
• W2989938285 hasConceptScore W2989938285C186000732 @default.
• W2989938285 hasConceptScore W2989938285C190283241 @default.
• W2989938285 hasConceptScore W2989938285C2780110267 @default.
• W2989938285 hasConceptScore W2989938285C29537977 @default.
• W2989938285 hasConceptScore W2989938285C31573885 @default.
• W2989938285 hasConceptScore W2989938285C502942594 @default.
• W2989938285 hasConceptScore W2989938285C530470458 @default.
• W2989938285 hasConceptScore W2989938285C54355233 @default.
• W2989938285 hasConceptScore W2989938285C55493867 @default.
• W2989938285 hasConceptScore W2989938285C62478195 @default.
• W2989938285 hasConceptScore W2989938285C75217442 @default.
• W2989938285 hasConceptScore W2989938285C86554907 @default.
• W2989938285 hasConceptScore W2989938285C86803240 @default.
• W2989938285 hasConceptScore W2989938285C95444343 @default.
• W2989938285 hasConceptScore W2989938285C98490376 @default.
• W2989938285 hasLocation W29899382851 @default.
• W2989938285 hasOpenAccess W2989938285 @default.
• W2989938285 hasPrimaryLocation W29899382851 @default.
• W2989938285 hasRelatedWork W10043079 @default.
• W2989938285 hasRelatedWork W22357311 @default.
• W2989938285 hasRelatedWork W2639860 @default.
• W2989938285 hasRelatedWork W33023422 @default.
• W2989938285 hasRelatedWork W34817941 @default.
• W2989938285 hasRelatedWork W35007230 @default.
• W2989938285 hasRelatedWork W30453819 @default.
• W2989938285 hasRelatedWork W34208466 @default.
• W2989938285 hasRelatedWork W5184789 @default.
• W2989938285 hasRelatedWork W8423774 @default.
• W2989938285 isParatext "false" @default.
• W2989938285 isRetracted "false" @default.
• W2989938285 magId "2989938285" @default.
• W2989938285 workType "article" @default.